GAITHERSBURG, Md., April 25, 2013 /PRNewswire/ -- Quanta BioSciences today announced the CDC Real-Time RT-PCR (rRT-PCR) Protocol LP-152 for Detection and Characterization of Avian A/H7 (Eurasian-lineage) Influenza recommends that public health and other qualified laboratories utilize Quanta's qScript One-Step qRT-PCR Kit, Low ROX (95059-200 and 95059-050).
According to the World Health Organization (WHO) 108 cases of H7N9 influenza have been reported in China, causing severe respiratory illness including 22 deaths, as of April 23. Whether person-to-person transmission of this virus is possible is unclear, but other strains of Avian Influenza A, such as H5N1, have been spread via human-to-human interaction. With the potential threat of pandemic presented by any flu virus that can spread human-to-human, it is imperative that the best technologies are employed to detect and characterize these viruses.
In an effort to make supply of the qScript One-Step qRT-PCR technology available across the globe in reaction to the H7N9 outbreak, Quanta BioSciences has engaged its worldwide distribution network to ensure steady supply. For more information on this technology or to determine how to source these kits, please visit http://www.quantabio.com/avianflu.
About Quanta Biosciences:
Quanta BioSciences Inc., a U.S. based company, supplies superior quality reagents for demanding RT and PCR applications in life science, drug discovery and public health laboratories around the world. The Quanta BioSciences PCR and cDNA synthesis reagent portfolio defines the standard for reproducibility, specificity and sensitivity in the quantitative PCR market. The qScript technology named in CDC protocol LP-152 is part of a large family of polymerases designed and built for robust quantitative amplification and detection.
Media Contact: Will Geist, Quanta BioSciences, +1 800-364-2149, ext. 702 or email [email protected]
SOURCE Quanta BioSciences